Drug-coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: 12-month Results from the IN.PACT SFA Randomized Trial

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2014 Dec 5

PMID 25472980

Citations 166

Authors

Gunnar Tepe

John Laird

Peter Schneider

Marianne Brodmann

Prakash Krishnan

Antonio Micari

Christopher Metzger

Dierk Scheinert

Thomas Zeller

David J Cohen

David B Snead

Beaux Alexander

Mario Landini

Michael R Jaff

Affiliations

Soon will be listed here.

Abstract

Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease.

Methods And Results: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94 ± 4.89 and 8.81 ± 5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedure-related deaths and no major amputations.

Conclusions: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease.

Clinical Trial Registration Url: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and NCT01566461.

Citing Articles

Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis.

Schwartz A, Shah Y, Huang H, Nathan A, Fanaroff A, Giri J J Soc Cardiovasc Angiogr Interv. 2025; 4(1):102432.

PMID: 40061407 PMC: 11887560. DOI: 10.1016/j.jscai.2024.102432.

The Impact of Peripheral Vascular Motion on Acute Drug Retention of Intravascular Devices.

Ursillo T, Lowry K, Allred C, Phillips M, Liu L, Chen D Cardiovasc Eng Technol. 2025; .

PMID: 39948327 DOI: 10.1007/s13239-025-00776-z.

Plaque morphological changes after drug-coated balloon angioplasty according to underlying plaque components.

Fujisawa N, Shimada T, Otsuka K, Yamazaki T, Fukuda D J Vasc Surg Cases Innov Tech. 2025; 11(1):101651.

PMID: 39850655 PMC: 11754128. DOI: 10.1016/j.jvscit.2024.101651.

Comparison of clinical outcomes of drug-coated balloons angioplasty vs. plain old balloons angioplasty for peripheral arterial disease: an umbrella meta-analysis.

Li J, Lu W, Lin L, Wu J, Cheng G, Hu Q Front Cardiovasc Med. 2024; 11:1511268.

PMID: 39639978 PMC: 11617568. DOI: 10.3389/fcvm.2024.1511268.

The Role of Cardio-Renal Inflammation in Deciding the Fate of the Arteriovenous Fistula in Haemodialysis Therapy.

Kane J, Lemieux A, Baranwal G, Misra S Cells. 2024; 13(19.

PMID: 39404400 PMC: 11475948. DOI: 10.3390/cells13191637.

References

Laird J, Yeo K . The treatment of femoropopliteal in-stent restenosis: back to the future. J Am Coll Cardiol. 2011; 59(1):24-5. DOI: 10.1016/j.jacc.2011.09.037. View

Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K . Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2011; 59(1):16-23. DOI: 10.1016/j.jacc.2011.09.036. View

Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A . Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012; 19(5):571-80. DOI: 10.1583/JEVT-12-3926MR.1. View

Laird Jr J, Yeo K, Rocha-Singh K, Das T, Joye J, Dippel E . Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv. 2012; 80(5):852-9. DOI: 10.1002/ccd.23475. View

Werk M, Albrecht T, Meyer D, Ahmed M, Behne A, Dietz U . Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012; 5(6):831-40. DOI: 10.1161/CIRCINTERVENTIONS.112.971630. View

Saxon R, Chervu A, Jones P, Bajwa T, Gable D, Soukas P . Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery.... J Vasc Interv Radiol. 2013; 24(2):165-73. DOI: 10.1016/j.jvir.2012.10.004. View

Zeller T, Dake M, Tepe G, Brechtel K, Noory E, Beschorner U . Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013; 6(3):274-81. DOI: 10.1016/j.jcin.2012.12.118. View

Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A . 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv. 2013; 6(3):282-9. DOI: 10.1016/j.jcin.2013.01.128. View

Lammer J, Zeller T, Hausegger K, Schaefer P, Gschwendtner M, Mueller-Huelsbeck S . Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions.... J Am Coll Cardiol. 2013; 62(15):1320-7. DOI: 10.1016/j.jacc.2013.05.079. View

10.

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M . The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7(1):10-9. DOI: 10.1016/j.jcin.2013.05.022. View

11.

Liistro F, Angioli P, Porto I, Ricci L, Ducci K, Grotti S . Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014; 21(1):1-8. DOI: 10.1583/13-4420R.1. View

12.

Armstrong E, Saeed H, Alvandi B, Singh S, Singh G, Yeo K . Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther. 2014; 21(1):34-43. PMC: 8922726. DOI: 10.1583/13-4399MR.1. View

13.

Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G . Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014; 7(4):411-5. DOI: 10.1016/j.jcin.2013.11.020. View

14.

Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M . Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005; 45(2):312-5. DOI: 10.1016/j.jacc.2004.11.026. View

15.

Hirsch A, Haskal Z, Hertzer N, Bakal C, Creager M, Halperin J . ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for.... Circulation. 2006; 113(11):e463-654. DOI: 10.1161/CIRCULATIONAHA.106.174526. View

16.

Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W . Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354(18):1879-88. DOI: 10.1056/NEJMoa051303. View

17.

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67. DOI: 10.1016/j.jvs.2006.12.037. View

18.

Rocha-Singh K, Jaff M, Crabtree T, Bloch D, Ansel G . Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007; 69(6):910-9. DOI: 10.1002/ccd.21104. View

19.

Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J . Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a "real-world" setting. J Endovasc Ther. 2007; 14(4):452-9. DOI: 10.1177/152660280701400404. View

20.

Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi J . Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358(7):689-99. DOI: 10.1056/NEJMoa0706356. View